

People

Appointments

Amgen names David Beier as Senior Vice President, Global Government Affairs

Amgen (<http://www.amgen.com>) has announced that David Beier has been named Senior Vice President, Global Government Affairs. He will be responsible for the operations of Amgen's Washington DC office and the management of corporate regulatory and legislative issues.

George Marrow, Amgen's Executive Vice President of Global Commercial Operations, said: 'Drawing upon his strong government and industry experience, David will make a significant contribution to aligning Amgen's commercial interests with government affairs activities...'

Beier joins Amgen from the law firm Hogan and Hartson in Washington, DC; he also has extensive government affairs and public policy background. He replaces Pete Teeley, who is assuming a new role as government affairs advisor for Amgen.

Jay M. Green named Executive VP and Director, Corporate Development at Inyx

Inyx (<http://www.inyxinc.com>), a developer and manufacturer of specialized drug delivery pharma products with expertise in niche aerosol technologies, announced its appointment of Jay M. Green to the newly established position of Executive Vice President and Director of Corporate Development.

Jack Kachkar, Chairman of Inyx, said: 'Jay's responsibilities will include spearheading Inyx's corporate relations both with Wall Street and other important public constituencies...'

Prior to joining Inyx, Green served as Managing Director of Duncan Capital LLC. He has more than 20 years of experience in subjects as diverse as corporate officer with NYSE-listed companies, senior executive with a merchant banking/venture capital firm, as well as managing principle with several advisory firms.

Rene Bruno joins Pharsight

Pharsight Corporation (<http://www.pharsight.com>) has announced the appointment of Rene Bruno as Managing

Director of Drug Development Consulting Services for the company's European operations. Bruno's role in Europe will be to oversee client delivery services and expand Pharsight's services in the European market.

Prior to joining Pharsight, Bruno spent the past three years at Genentech, where he was most recently senior scientist and Head of the Pharmacometry unit. Upon his appointment, he said, 'Joining Pharsight presents a tremendous opportunity to extend the pioneering work that the company has already accomplished in helping pharmaceutical and biotech companies to optimize their approach to drug development.'

Pharsight is a leading provider of science and information technology-based software and consulting services to optimize clinical drug development.

Management rearrangement at Caliper

Caliper Technologies (<http://www.calipertech.com>) has announced recent reconfiguration of their management team. Anne Knopf-Sill will be moving from her present role as Vice President, Microfluidics R&D, to VP, Molecular Diagnostics. She will be succeeded in the role of VP, Microfluidics R&D by Andrea Chow.

In addition, Caliper has attracted two industry veterans to join the Senior Management Team: Yvonne Linney, as Senior Director, Microfluidics Marketing and Product Management, and Seth Cohen as Director of Application Scientists. Linney joins the company after 10 years at Amersham, most recently as the Director of Marketing for Genomics; Cohen is the former Program Director of Lead Discovery of Millennium Pharmaceuticals.

President of Biosciences Federation announced

Professor Sir Tom Blundell has accepted an invitation to become the second President of the Biosciences Federation (<http://www.bsfc.ac.uk>), as of 1 January 2004. He will succeed Professor Colin Blakemore who is leaving to become Chief Executive of the Medical Research Council.

Blundell is the Sir William Dunn Professor of Biochemistry and Chair of Biological Sciences at Cambridge University whose

particular research interests are structural biology and bioinformatics. He has also acted as a consultant or board member to several major pharma companies and co-founded Astex Technology in 1999.

Professor Blundell commented: 'I am delighted and honoured to be appointed... it is important that life scientists have a clear and coherent voice in this country, and it is an exciting and challenging time to contribute to the dialogue that we must have with Government, other policy-makers and the public.'

The Biosciences Federation has also appointed Mike Withnall, who has served as Director for much of 2003, as its first Chief Executive.

Awards

David Clark wins prestigious Corwin Hansch Award

Argenta Discovery (<http://www.argentadiscovery.com>) has announced that David E. Clark, Director of Computer-Aided Drug Design, has been awarded the prestigious Corwin Hansch Award. This has been awarded to Clark for his work on quantitative structure-activity relationships (QSAR) and is presented by the QSAR and Modelling Society.

Yvonne C. Martin, Chair of the QSAR and Modelling Society, commented: 'Clark is a young investigator... he has established extensively on his imaginative work on 3D database searching, genetic algorithms in computational chemistry, *de novo* structure design and, more recently using QSAR to predict ADME properties.'

Clark completed his first degree in Chemistry from the University of Oxford and was awarded his MSc and PhD in Information Studies from Sheffield University.

Anthony Baxter, CEO of Argenta, said: 'David is a highly accomplished scientist with a flair for applying computational techniques to the chemical and biological challenges faced during the identification and optimization of potential drug compounds.'

People was written by Joanne Clough